Drug intelligence / Profile preview

DISC-203

Development stage: Preclinical
Lead developer: Dualitas Therapeutics
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

DISC-203 is an early-stage discovery program being developed by Dualitas Therapeutics (formerly Dual Therapeutics) for the treatment of autoimmune diseases. It is a bispecific antibody identified through the company's proprietary DualScreen™ Bispecific Discovery Engine. While the specific molecular targets and mechanism of action have not been publicly disclosed, the candidate is designed to leverage bispecificity to modulate immune pathways involved in autoimmunity. As of 2024, the program remains in the preclinical discovery phase.

Beyond the preview

Go deeper on DISC-203.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DISC-203.

Explore the full profile